Subscribe To
Onl therapeutics completes enrollment in phase 2 study of first-in-class fas-inhibitor in patients with macula-off rhegmatogenous retinal detachment
More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 Ophthalmic Solution as adjunct t...
August 28, 2023, 11:00 am
bito suddenly has a double-digit dividend yield but this may not matter
bito is a Bitcoin ETF that holds Bitcoin futures contracts. The fund surprised many investors this year...
August 27, 2023, 8:23 am
Merck and eisai cull late-stage study for head and neck cancer therapy
Merck & Co Inc (NYSE:MRK) and research partner Eisai said they are halting a late-stage trial that used a combination of drugs to treat a type of head...
August 25, 2023, 7:58 am
Amc stock drops after reverse split takes effect
Leading exhibitor AMC Entertainment completed a 1-for-10 reverse stock split this morning, a planned mo...
August 24, 2023, 12:56 pm
Aptose to present at the h.c. wainwright 25th annual global investment conference
SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clin...
August 24, 2023, 7:30 am
Eli lilly reports positive results from study of thyroid cancer treatment
Eli Lilly & Co. LLY, +0.66% on Tuesday reported positive results from a study evaluating its targeted therapy Retevmo versus the current standard init...
August 22, 2023, 8:32 am
Inhibikase therapeutics to present at the international congress of parkinson's disease and movement disorders
BOSTON and ATLANTA , Aug. 22, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmace...
August 22, 2023, 8:05 am
Deciphera pharmaceuticals: clawing its way back
Deciphera Pharmaceuticals is focused on the development of their multikinase inhibitor ripretinib for t...
August 22, 2023, 5:06 am
Enliven therapeutics: preclinical company with interesting value proposition
Enliven Therapeutics, Inc. is a recently merged biopharma company focused on developing oncology candidates for leukemia and lymphoma. The company has...
August 18, 2023, 12:57 pm
Atopic dermatitis market to reach us$ 62.7 billion, with double digit cagr of 24% | fact.mr
[Updated Report 2022-2032] Atopic Dermatitis Market Analysis By Drug Class (Corticosteroids, PDE4 Inhibito...
August 18, 2023, 7:07 am
Ivanhoe announces mou to begin export of copper concentrate via angolan lobito ocean port
(Kitco News) - The company said that up to 10,000 tonnes of copper concentrate to be exported via Angolan Lobi...
August 16, 2023, 2:17 pm
Meet industry leading brands at fmls:23
The Finance Magnates London Summit (FMLS) has emerged as a landmark event that brings together industry-leading brands. Nowhere is this more apparent ...
August 15, 2023, 7:45 am
Replimune: q4 2023 data readouts of rp1 makes this a must watch
Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous s...
August 14, 2023, 5:28 pm
Applied therapeutics reports second quarter 2023 financial results
Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the FDA...
August 10, 2023, 11:00 am
Amc entertainment rides box office revival to top q2 forecasts
Top exhibitor AMC Entertainment rode the box office revival in the second quarter, beating Wall Street ...
August 8, 2023, 6:57 am
Early bird prices now available for fmls:23
With summer in full swing, the time to look ahead to the biggest event of the Fall is now. This includes the budding anticipation for Finance Magnates...
August 3, 2023, 9:07 am
Checkpoint: pdufa date catalyst makes this a must watch
A PDUFA date of January 3, 2024 has been established by which FDA will decide upon by then whether or not cosibelimab should be approved for the treat...
August 1, 2023, 7:01 pm
Bristol-myers squibb's bright future unfolds beyond q2 2023 turmoil
Bristol-Myers Squibb's revenue for the second quarter of 2023 was $11.23 billion, down 0.97% from the previous quarter and 5.6% from the second quarte...
July 29, 2023, 8:03 am
Curis to release second quarter 2023 financial results and hold conference call on august 3, 2023
LEXINGTON, Mass. , July 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an ora...
July 27, 2023, 6:25 pm
bito: finally attractive now that it can be hedged through bitx.
Now that BITX exists, a position in bito can be hedged. Both bi...
July 22, 2023, 12:57 pm